A machine learning (ML) model using electronic medical record (EMR) data from 396,000 Mayo Clinic primary care patients identified undiagnosed psoriatic arthritis (PsA) with area under the curve (AUC) 79.6%. Key predictors: psoriasis, joint pain, tenosynovitis, https://t.co/VsYevnJEjK

In 1314 PsA patients, cumulative methotrexate dose was not associated with liver fibrosis (OR 0.99). Instead, higher BMI (OR 1.03) & diabetes (OR 5.03) were key drivers. MASLD, not MTX, may underlie fibrosis risk in PsA. APRI >0.7 used for fibrosis detection. Abstract#POS0111 https://t.co/zsX7NUOT9m

#EULAR2025 Abstr#OP0273 Single arm, Open Label Phase 2 trial showed Certolizumab (given in WKS 8-28) +LMWH+LDA in Antiphospholipid syndrome reported 20% Adverse Pregnancy Outcomes in ITT; 18% Per Protocol. Met prespecified criterion (20%); expected LMWH+LDA (40%) @RheumNow https://t.co/ynQ2h2NTQ7

Late-Onset Disease: Different Age, Different Rules? We’re seeing more patients develop rheumatic diseases for the first time in their 60s, 70s, or beyond. But are these truly the same diseases we see in younger adults, or do they behave differently, shaped by age-related https://t.co/Txvr62UpWZ

Should we screen for #lung #cancer in #SSc high risk Pts? When >10 yrs? Greek cohort of SSc since 1995 Disease duration 12 yrs, smoking lung ca group ⬆️58% vs 29% ⬆️dcSSc ⬆️immunosuppression OR >4X lung ca if dcSSc, IS Less #DU #PO0940 @RheumNow @eular_org #EULAR2025 https://t.co/L2zEkP8pAc

In CareRA pooled analysis, 1 in 3 early RA pts had persistent impact (pain, fatigue, HAQ) despite improved inflammation. Female sex, longer symptom duration & low CRP were predictive. Pts more often escalated to b/tsDMARDs → risk of overtreatment? @RheumNow #EULAR2025 #OP0330

Some RA-ILD is less of a worry, some is critical. How do we stratify? Great modelling work from Korea & @jeffsparks - model stratifying really well, even without KL-6. We need to do this more, so we can go really hard early when we need to. #EULAR2025 OP0329 @RheumNow https://t.co/i2djatO3F2

🌍Patients w RMDs across 🇫🇷🇳🇱🇨🇭🇹🇷 face different barriers to physical activity: 💶Cost =barrier in 🇳🇱 ⛈️Weather =barrier in 🇹🇷 🧑‍⚕️HCP support =key in 🇫🇷 🏃Active transport & knowledge =enablers in 🇨🇭 Tailored physical activity interventions needed. @RheumNow #EULAR2025 #OP0382-HPR https://t.co/lk7fwDHDe7